Anbio Biotechnology Class A Ordinary Shares
NNNNAnbio Biotechnology is a biopharmaceutical company focused on the development and commercialization of innovative therapies, particularly in the fields of cancer treatment and immune modulation. The company emphasizes research and development to bring novel drugs to market, aiming to address unmet medical needs.
Company News
The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.
Anbio Biotechnology launched a Chikungunya IgM/IgG Rapid Test and an AP-100 Ultra-Fast PCR system to support rapid diagnostic testing for infectious diseases, enabling quick detection of pathogens in both centralized and decentralized healthcare settings.
Amaran Biotechnology, a subsidiary of OBI Pharma, and Nippon Fine Chemical, a Japanese company, have signed an MOU to collaborate in nanoparticle-based drug CDMO manufacturing. The partnership aims to leverage their respective strengths to expand their presence in Taiwan, Japan, and international CDMO markets.
